>
Switch to:

Illumina ROCE %

: 4.19% (As of Mar. 2022)
View and export this data going back to 2000. Start your Free Trial

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Illumina's annualized ROCE % for the quarter that ended in Mar. 2022 was 4.19%.

Illumina ROCE % Historical Data

The historical data trend for Illumina's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Illumina Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
ROCE %
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 26.71 19.68 19.82 13.93 9.24

Illumina Quarterly Data
Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22
ROCE % Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 10.88 11.67 15.82 2.80 4.19

Illumina ROCE % Calculation

Illumina's annualized ROCE % for the fiscal year that ended in Dec. 2021 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2021 )  (A: Dec. 2020 )(A: Dec. 2021 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2021 )  (A: Dec. 2020 )(A: Dec. 2021 )
=945/( ( (7585 - 1244) + (15217 - 1093) )/ 2 )
=945/( (6341+14124)/ 2 )
=945/10232.5
=9.24 %

Illumina's ROCE % of for the quarter that ended in Mar. 2022 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Mar. 2022 )  (Q: Dec. 2021 )(Q: Mar. 2022 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Mar. 2022 )  (Q: Dec. 2021 )(Q: Mar. 2022 )
=584/( ( (15217 - 1093) + (15274 - 1490) )/ 2 )
=584/( ( 14124 + 13784 )/ 2 )
=584/13954
=4.19 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2022) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Illumina  (NAS:ILMN) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Illumina ROCE % Related Terms

Thank you for viewing the detailed overview of Illumina's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Illumina Business Description

Illumina logo
Industry
Healthcare » Medical Diagnostics & Research NAICS : 621511 SIC : 8071
Comparable Companies
XSWX:LONN SHSE:603259 NYSE:IQV NAS:IDXX NYSE:A NYSE:MTD NYSE:LH NYSE:PKI XPAR:ERF NAS:ICLR
Traded in Other Exchanges
ILMN:Mexico 0J8Z:UK ILU:Germany ILU:Germany ILU:Germany I1LM34:Brazil ILMN:Austria
Address
5200 Illumina Way, San Diego, CA, USA, 92122
Website
https://www.illumina.com
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates revenue from sequencing tools and dedicated consumables (76% of 2020 sales). Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications. Services account for 16% of sales and include basic maintenance services, clinical lab applications (such as noninvasive prenatal, oncology, and rare-disease screening), and whole genome sequencing.
Executives
Flatley Jay T director 9885 TOWNE CENTRE DR SAN DIEGO CA 92121
Tousi Susan H officer: SVP Product Development 5200 ILLUMINA WAY SAN DIEGO CA 92122
Reeves Kathryne Gambrell officer: SVP, Chief Marketing Officer 5200 ILLUMINA WAY SAN DIEGO CA 92122
Goswami Joydeep officer: SVP Corp Business Development SUMITOMO FUDOSAN MITA TWIN BLDG EAST WING 4-2-8 SHIBAURA MINATO-KU TOKYO M0 1080023
Dadswell Charles officer: SVP & General Counsel 5200 ILLUMINA WAY SAN DIEGO CA 92122
Desouza Francis A director, officer: President and CEO 350 ELLIS STREET MOUNTAIN VIEW CA 94043
Van Oene Mark officer: SVP Chief Commercial Officer 5200 ILLUMINA WAY SAN DIEGO CA 92122
Ragusa Robert P officer: SVP, Global Quality & Ops PUBLIC "-//W3C//DTD HTML 4.0 Transitional//EN"> Ownership Information: RAGUSA ROBERT P a.header:link {color: #3b4fae; font-weight: bold; text-decoration: underline;} a.header:visited {color: #3b4fae; font-weight: bold; text-decoration: underline;} a.header:hover {color: #191970;}
Mcginnis Karen K officer: VP, Chief Accounting Officer INSIGHT ENTERPRISES INC 1305 WEST AUTO DRIVE TEMPE AZ 85284
Hoyt Aimee L officer: SVP, Chief People Officer 5200 ILLUMINA WAY SAN DIEGO CA 92122
Ronaghi Mostafa officer: SVP, Entrepreneurial Devlopmt 9885 TOWNE CENTRE DRIVE SAN DIEGO CA 92121
Aravanis Alexander officer: SVP, Chief Technology Officer 5200 ILLUMINA WAY SAN DIEGO CA 92122
Siegel Susan E director 3000 SAND HILL ROAD BLDG 3 STE 290 MENLO PARK CA 94025
Thompson John Wendell director C/O MICROSOFT CORPORATION ONE MICROSOFT WAY REDMOND WA 98053
Epstein Robert S director PUBLIC "-//W3C//DTD HTML 4.0 Transitional//EN"> Ownership Information: EPSTEIN ROBERT S a.header:link {color: #3b4fae; font-weight: bold; text-decoration: underline;} a.header:visited {color: #3b4fae; font-weight: bold; text-decoration: underline;} a.header:hover {color: #191970;}

Illumina Headlines

From GuruFocus

GRAIL Announces Partnership with Alignment Health Plan as First Medicare Advantage Plan to Offer Galleri® Multi-Cancer Early Detection Blood Test

By Business Wire 12-06-2021

Illumina collaborates with Nashville Biosciences to accelerate medicines development

By PRNewswire 01-10-2022

Financial Consulate, Inc Buys iShares J.P. Morgan EM Corporate Bond ETF, Exxon Mobil Corp, Royalty Pharma PLC, Sells Invesco S&P 500 Equal Weight Financials ETF, Vanguard S&P 500 ETF, CrowdStrike Holdings Inc

By insider 02-07-2022

Telos Capital Management, Inc. Buys Illumina Inc, United Parcel Service Inc, Newell Brands Inc, Sells Activision Blizzard Inc, iShares Biotechnology ETF, Merck Inc

By insider 01-21-2022

Illumina collaborates with National Cancer Center Japan to address a leading cause of death in Asia

By PRNewswire 01-24-2022

Geo Capital Gestora de Recursos Ltd Buys Illumina Inc, Deere, Meta Platforms Inc, Sells Cerner Corp, Marriott International Inc, Palo Alto Networks Inc

By insider 02-15-2022

Illumina Partners with Agendia to Expand Genomic Testing in Breast Cancer Care

By PRNewswire 01-10-2022

Illumina partners with centers across France to advance a precision medicine approach for patients with late-stage cancer

By PRNewswire 02-03-2022

Illumina and Sequoia Capital China Select First Startups to join Genomics Incubator in China

By PRNewswire 11-17-2021

Vontobel Holding Ltd. Buys Illumina Inc, Sells Intuitive Surgical Inc, Arista Networks Inc, InMode

By insider 02-11-2022

Other Sources

Why Illumina Stock Just Jumped 9.5%

By Fool 2022-01-11

Company News for Jan 12, 2022

By Zacks 2022-01-12

What's the Outlook for Illumina?

By Fool 2022-01-23

Illumina (ILMN) Debuts TSO Comprehensive Test in Europe

By Zacks 2022-03-18

Illumina's (ILMN) GRAIL, Point32Health Unite to Offer MCED Test

By Zacks 2022-02-16

$ILMN - Illumina, Inc. (ILMN) JPMorgan 40th Annual Healthcare Conference (Transcript). Illumina Inc Ilmn Jpmorgan 40th Annual Healthcare Conference Transcript

By Seekingalpha 2022-01-10

$ILMN - Illumina, Inc. (ILMN) CEO Francis deSouza Presents at Cowen Health Care Conference (Transcript).…

By Seekingalpha 2022-03-07

These 2 Nasdaq Winners Are Lighting Up the Market Tuesday

By Fool 2022-01-11

Illumina (ILMN) Announces Preliminary Q4 Sales, Issues '22 View

By Zacks 2022-01-11

Why Illumina (ILMN) is Poised to Beat Earnings Estimates Again

By Zacks 2022-01-13

Illumina (ILMN) Invests in Seven Additional Genomics Startups

By Zacks 2022-03-18

$ILMN - Illumina's (ILMN) CEO Francis deSouza on Q4 2021 Results - Earnings Call Transcript.…

By Seekingalpha 2022-02-10

Top Research Reports for Merck, Shopify & Intercontinental Exchange

By Zacks 2022-02-18

How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings

By Zacks 2022-02-10

Illumina (ILMN) Ties Up With Syapse to Evaluate Biomarker Testing

By Zacks 2022-01-05

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)